Irritable Bowel Syndrome Treatment Viberzi Now Available

Allergan's eluxadoline, a treatment for irritable bowel syndrome with diarrhea, is now available by prescription.

Allergan’s eluxadoline (Viberzi), a treatment for irritable bowel syndrome (IBS) with diarrhea, is now available by prescription.

Viberzi, which is taken orally, was shown to relieve symptoms in 2 clinical trials, according to the manufacturer.

"We are excited about the launch of Viberzi, which addresses an unmet need among IBS-D patients seeking a treatment to manage their symptoms proactively," said William Meury, president and executive vice president of Branded Pharma at Allergan, in a press release. "This introduction reaffirms Allergan's commitment to providing a new treatment option that serves to help gastroenterologists reach better outcomes for their patients."

The Drug Enforcement Agency recently completed its review of the medication and placed it into Schedule IV of the Controlled Substance Act, meaning Viberzi has a low potential of dependence or abuse.

Adverse effects associated with Viberzi include constipation, nausea, and abdominal pain.

In a press release, Allergan noted that there are few prescription treatment options for IBS with diarrhea that can relieve both diarrhea and abdominal pain.

The condition affects around 15 million Americans.